OABI

$1.83

Market ClosedAs of Mar 17, 8:00 PM UTC

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.83
Potential Upside
5%
Whystock Fair Value$1.92
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The compa...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$264.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-23.36%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.78

Recent News

Motley Fool
Mar 15, 2026

OmniAb (OABI) Q4 2025 Earnings Call Transcript

By year-end, we are happy to report that we had 107 partners who are running 407 active programs. As our partner pipeline advances, certain later-stage programs are now coming into focus with the potential to drive meaningful milestone revenue and create value over time, headed toward the generation of significant future recurring royalty revenue streams. Additionally, we are building a strong foundation for our Exploration platform, which brings our high-throughput single B-cell screening capabilities directly into our partners' labs.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 5, 2026

OmniAb, Inc. Q4 2025 Earnings Call Summary

Moby summary of OmniAb, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Mar 5, 2026

OmniAb Inc (OABI) Q4 2025 Earnings Call Highlights: Strong Partner Engagement and New ...

OmniAb Inc (OABI) showcases robust partner growth and innovative platforms, despite facing revenue declines and financial hurdles.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 5, 2026

OmniAb Q4 Earnings Call Highlights

OmniAb (NASDAQ:OABI) outlined progress in expanding its partner base and advancing partner programs while reporting lower 2025 revenue and reduced operating expenses, according to management’s comments on the company’s financial results and business update conference call held March 4, 2026. Partne

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 4, 2026

OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -33.33% and -5.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.